Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2024
Tsiampali, C., Vachliotis I. D., Goulas A., & Polyzos S. A. (2024).  Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease.. Hormones (Athens).
Makri, E., Orfanidou M., Makri E. S., Goulas A., Terpos E., & Polyzos S. A. (2024).  Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.. J Clin Exp Hepatol. 14(3), 101353.
Makri, E. S., Evripidou K., & Polyzos S. A. (2024).  Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Serbis, A., Polyzos S. A., Paschou S. A., Siomou E., & Kiortsis D. N. (2024).  Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?. Endocrine.
Papadimitriou, K., Mousiolis A. C., Mintziori G., Tarenidou C., Polyzos S. A., & Goulis D. G. (2024).  Hypogonadism and nonalcoholic fatty liver disease.. Endocrine.
Kountouras, J., Kazakos E., Polyzos S. A., & Zavos C. (2024).  Letter to the Editor: Comment on: Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers.. J Gastrointest Cancer.
Polyzos, S. A., & Goulis D. G. (2024).  Menopause and metabolic dysfunction-associated steatotic liver disease.. Maturitas. 108024.
Polyzos, S. A., & Mantzoros C. S. (2024).  Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.. Metabolism. 155936.
Makri, E. S., Xanthopoulos K., Parasidis P. Mavrommati, Makri E., Pettas S., Tsingotjidou A., et al. (2024).  Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease.. Endocrine.
Polyzos, S. A., & Targher G. (2024).  Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.. Curr Obes Rep.
2023
Doulberis, M., Kountouras J., Stadler T., Meerwein C., Polyzos S. A., Kulaksiz H., et al. (2023).  Association between Infection and Nasal Polyps: A Systematic Review and Meta-Analysis.. Microorganisms. 11(6), 
Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., et al. (2023).  Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.. Endocrine. 81(3), 573-578.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Vardaka E., Kyrailidi F., Mouratidou M. C., et al. (2023).  Autonomic Dysfunction and Somatization in Young Patients With Irritable Bowel Syndrome and Mitral Valve Prolapse Syndrome.. J Neurogastroenterol Motil. 29(3), 403-404.
Kountouras, J., Doulberis M., Papaefthymiou A., Polyzos S. A., Zavos C., Kazakos E., et al. (2023).  Controlling the Impact of -Related Hyperhomocysteinemia on Neurodegeneration.. Medicina (Kaunas). 59(3), 
Raptis, D. D., Mantzoros C. S., & Polyzos S. A. (2023).  Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.. Ther Clin Risk Manag. 19, 77-96.
Seo, Y-G., Polyzos S. A., Park K-H., & Mantzoros C. S. (2023).  Fibrosis-4 index predicts long-term all-cause, cardiovascular and liver-related mortality in the adult Korean population.. Clin Gastroenterol Hepatol.
Anastasilakis, A. D., Makras P., Polyzos S. A., & Papapoulos S. E. (2023).  The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.. Calcif Tissue Int.
Ntona, S., Papaefthymiou A., Kountouras J., Gialamprinou D., Kotronis G., Boziki M., et al. (2023).  Impact of nonalcoholic fatty liver disease-related metabolic state on depression.. Neurochem Int. 163, 105484.
Kountouras, J., Kazakos E., Kyrailidi F., Polyzos S. A., Zavos C., Arapoglou S., et al. (2023).  Innate immunity and nonalcoholic fatty liver disease.. Ann Gastroenterol. 36(3), 244-256.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kazakos E., Tzilves D., Touloumtzi M., et al. (2023).  Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.. Aliment Pharmacol Ther. 57(10), 1186-1187.
Kountouras, J., Kazakos E., Gatopoulou A., Polyzos S. A., Touloumtzi M., Kyrailidi F., et al. (2023).  Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels.. Aliment Pharmacol Ther. 58(11-12), 1252-1253.
Anastasilakis, A. D., Polyzos S. A., Vorkas P. A., Gkiomisi A., Yavropoulou M. P., Rauner M., et al. (2023).  Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study.. J Clin Med. 12(16), 
Kouvari, M., Valenzuela-Vallejo L., Guatibonza-Garcia V., Polyzos S. A., Deng Y., Kokkorakis M., et al. (2023).  Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.. Metabolism. 147, 155666.
Polyzos, S. A., & Kountouras J. (2023).  Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?. Curr Vasc Pharmacol.
Polyzos, S. A., Chrysavgis L., Vachliotis I. D., Chartampilas E., & Cholongitas E. (2023).  Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.. Semin Cancer Biol. 93, 20-35.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.